Get started
TEVA PHARMACDRNTEVA PHARMACDRNTEVA PHARMACDRN

TEVA PHARMACDRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

T1EV34 trade ideas

$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit. Earnings (loss) per share attributable to ordinary shareholders: Basic ($) 2020 - Lower? 2019 - (0.91) even lower? 2018 - (2.35) Lower loss 2017 - (16.26) Huge loss 2016 - 0.07 Smaller profit 2015 - 1.84 Profit Diluted ($) 2019 - (0.91) 2018 - (2.35) 2017 - (16.26) 2016 - 0.07 2015 -1.82 www.sec.gov
NYSE:TEVALong
by AaronX
Teva Pharmaceutical Industries Ltd covic-19 Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need. "We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost," said Brendan O’Grady, Teva Executive Vice President, North America Commercial. "Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately." Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month. Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients. Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.
NYSE:TEVALong
by Bullishcharts
1